[go: up one dir, main page]

ES2528957T3 - Forma cristalina del cloruro de glicopirronio - Google Patents

Forma cristalina del cloruro de glicopirronio Download PDF

Info

Publication number
ES2528957T3
ES2528957T3 ES11735781.4T ES11735781T ES2528957T3 ES 2528957 T3 ES2528957 T3 ES 2528957T3 ES 11735781 T ES11735781 T ES 11735781T ES 2528957 T3 ES2528957 T3 ES 2528957T3
Authority
ES
Spain
Prior art keywords
crystalline form
chloride
glycopyrronium chloride
glycopyrronium
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11735781.4T
Other languages
English (en)
Inventor
Fausto Pivetti
Monica Bocchi
Enrico Vigano'
Ernesto Landonio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Application granted granted Critical
Publication of ES2528957T3 publication Critical patent/ES2528957T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cloruro de (3R,2'S)- y (3S,2'R)-[(ciclopentil-hidroxifenilacetil)oxi]-1,1-dimetilpirrolidinio cristalino (cloruro de treo glicopirronio) monohidrato, que tiene los siguientes picos XRPD característicos a 2θ en grados angulares usando radiación Cu-Kα (precisión ± 0,1°): 5,40; 10,65; 11,32; 12,46; 14,88; 17,16; 18,47; 18;69; 19,24; 22,08; 22,74; 25,40; 25,54; 26,57; y 28,40.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8

Claims (1)

  1. imagen1
ES11735781.4T 2010-06-14 2011-06-13 Forma cristalina del cloruro de glicopirronio Active ES2528957T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10165786 2010-06-14
EP10165786 2010-06-14
PCT/EP2011/002893 WO2011157387A1 (en) 2010-06-14 2011-06-13 Crystal form of glycopyrronium chloride

Publications (1)

Publication Number Publication Date
ES2528957T3 true ES2528957T3 (es) 2015-02-13

Family

ID=42751657

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11735781.4T Active ES2528957T3 (es) 2010-06-14 2011-06-13 Forma cristalina del cloruro de glicopirronio

Country Status (10)

Country Link
US (1) US9174937B2 (es)
EP (1) EP2580195B1 (es)
KR (1) KR101736529B1 (es)
CN (1) CN102939280B (es)
AR (1) AR081889A1 (es)
BR (1) BR112012031451A2 (es)
CA (1) CA2802584C (es)
ES (1) ES2528957T3 (es)
RU (1) RU2569852C2 (es)
WO (1) WO2011157387A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160081989A (ko) 2013-02-28 2016-07-08 더미라, 인코포레이티드 글리코피롤레이트 염
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
BR112016008161B1 (pt) 2013-10-22 2022-11-29 Chiesi Farmaceutici S.P.A Processos para preparar um composto, compostos intermediários, forma cristalina de um composto, uso de uma forma cristalina de um composto e solvato de um composto
US9926270B2 (en) 2014-08-20 2018-03-27 Dermira, Inc. Process for production of glycopyrronium tosylate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
ATE238280T1 (de) * 1996-11-11 2003-05-15 Christian R Noe Verwendung eines pharmazeutisch geeigneten salzes von (3r,2'r)-3-((cyclopentyl- hydroxyphenylacetyl)oxy)-1,1-dimethyl- pyrrolidinium zur herstellung eines arzneimittels
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
AT412088B (de) * 2002-12-18 2004-09-27 Pharmacon Forschung & Beratung Gmbh Verfahren zur herstellung der r,r oder s,s konfigurierten glycopyrronium-isomere
WO2005082413A2 (en) * 2004-02-27 2005-09-09 Altana Pharma Ag Ciclesonide and glycopyrronium combination
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
GB0504463D0 (en) * 2005-03-03 2005-04-13 Arakis Ltd Method of crystallisation and purification
JP2008534480A (ja) * 2005-03-24 2008-08-28 ソーセイ アールアンドディ リミテッド グリコピロニウム塩およびそれらの治療的使用
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
MX344153B (es) * 2009-04-09 2016-12-07 Novartis Ag Proceso para la preparación de sales de pirrolidinio.

Also Published As

Publication number Publication date
WO2011157387A1 (en) 2011-12-22
CA2802584C (en) 2018-08-21
RU2569852C2 (ru) 2015-11-27
CA2802584A1 (en) 2011-12-22
US20110305645A1 (en) 2011-12-15
CN102939280A (zh) 2013-02-20
HK1177200A1 (en) 2013-08-16
KR20130119844A (ko) 2013-11-01
KR101736529B1 (ko) 2017-05-17
BR112012031451A2 (pt) 2016-12-06
AR081889A1 (es) 2012-10-24
EP2580195B1 (en) 2014-12-03
US9174937B2 (en) 2015-11-03
RU2012154006A (ru) 2014-07-20
EP2580195A1 (en) 2013-04-17
CN102939280B (zh) 2014-11-19

Similar Documents

Publication Publication Date Title
ES2528026T3 (es) Sales de oxalato de ivabridina cristalino y polimorfos de los mismos
ES2528957T3 (es) Forma cristalina del cloruro de glicopirronio
ES2500067T3 (es) Compuesto bicíclico y uso del mismo para fines médicos
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
EP2881384A8 (en) Partially saturated nitrogen-containing heterocyclic compound
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
CY1118993T1 (el) Υποκατεστημενες ενωσεις τετραϋδροϊσοκινολινης ως αναστολεις τελεστη xiα
CR20120397A (es) Inhibidores del virus de la hepatitis c
ME02558B (me) Inhibitori replikacije virusa gripa
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
EA201070786A1 (ru) Бензофуропиримидиноны
EA201170434A1 (ru) Макроциклические ингибиторы сериновых протеаз гепатита с
CY1118128T1 (el) Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2
NZ631477A (en) Substituted pyrrolidine-2-carboxamides
ATE519764T1 (de) Spiroindolinon-derivate
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
RU2012148909A (ru) Новый синтез соединений тиазолидиндиона
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
AU2012310674B2 (en) Radioactive fluorine labeled compound
AR087672A1 (es) Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer
ES2541857T3 (es) Procesos para preparar ciclopropilamidas e intermedios asociados con estas
HRP20170080T1 (hr) Spojevi azetidiniloksifenilpirolidina
GB201305247D0 (en) Amide Compounds
CY1114020T1 (el) 3-αμινοκυκλοπεντανοκαρβοξαμιδια ως διαμορφωτες υποδοχεα χημοκινης
MX2010010876A (es) Piperidinas sustituidas como compuestos terapeuticos.